This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Lynch HT , Casey MJ , Snyder CL , Bewtra C , Lynch JF , Butts M , Godwin AK
Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management
Molecular Oncology. 2009 Apr;3(2) :97-137
PMID: ISI:000265995900005 PMCID: PMC2778287
AbstractHereditary ovarian cancer accounts for at least 5% of the estimated 22,000 new cases of this disease during 2009. During this same time, over 15,000 will die from malignancy ascribed to ovarian origin. The bulk of these hereditary cases fits the hereditary breast-ovarian cancer syndrome, while virtually all of the remainder will be consonant with the Lynch syndrome, disorders which are autosomal dominantly inherited. Advances in molecular genetics have led to the identification of BRCA1 and BRCA2 gene mutations which predispose to the hereditary breast-ovarian cancer syndrome, and mutations in mismatch repair genes, the most common of which are MSH2 and MLH1, which predispose to Lynch syndrome. These discoveries enable relatively certain diagnosis, limited only by their variable penetrance, so that identification of mutation carriers through a comprehensive cancer family history might be possible. This paper reviews the subject of hereditary ovarian cancer, with particular attention to its molecular genetic basis, its pathology, and its phenotypic/genotypic heterogeneity. (C) 2009 Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies.
NotesLynch, Henry T. Casey, Murray Joseph Snyder, Carrie L. Bewtra, Chhanda Lynch, Jane F. Butts, Matthew Godwin, Andrew K. 331 ELSEVIER SCI LTD; THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND